Study title:
Phase II randomized study of immunotherapy of advanced breast cancer by repeated intramuscular injection of a recombinant vaccinia virus containing sequences coding for human MUC-1 and interleukin-2 (TG1031) comparing two doses levels
Date receipt dossier:
4 Jun 1998
Pharmaceutical study code:
TG1031.02
Company / Sponsor:
Transgene
Phase:
II
Treated organism:
Humans
Indication category:
Cancer therapy
Disease:
Metastatic adenocarcinoma of the Breast
Therapeutic approach:
Immunotherapy
Genetic modification:
Muc-1 and Interleukine 2 (IL-2)
Method of transfer of nucleic acid of interest:
Attenuated Vaccinia Virus (Copenhagen Strain)
Administered biological material:
Recombinant Attenuated Vaccinia Virus
Route of administration:
Intramuscular
Locations in Belgium:
Universitair Ziekenhuis Gent
Type of procedure:
Contained use only
Current status:
Authorized